Valencia Nutrition [VALENCIA] vs Biocon [BIOCON] Detailed Stock Comparison
Valencia Nutrition
BSE
Loading...
Biocon
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Valencia Nutrition wins in 9 metrics, Biocon wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Valencia Nutrition | Biocon | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 90.55 | 107.13 | Valencia Nutrition |
| Price-to-Book Ratio | 2.61 | 1.89 | Biocon |
| Debt-to-Equity Ratio | 4.06 | 66.26 | Valencia Nutrition |
| PEG Ratio | N/A | 34.45 | N/A |
| EV/EBITDA | 62.94 | 18.91 | Biocon |
| Profit Margin (TTM) | 12.68% | 2.44% | Valencia Nutrition |
| Operating Margin (TTM) | 34.22% | 7.46% | Valencia Nutrition |
| EBITDA Margin (TTM) | 34.22% | 7.46% | Valencia Nutrition |
| Return on Equity | 6.22% | 3.66% | Valencia Nutrition |
| Return on Assets (TTM) | 3.39% | 1.72% | Valencia Nutrition |
| Free Cash Flow (TTM) | $-235.15M | $17.18B | Biocon |
| Dividend Yield | N/A | 0.26% | N/A |
| 1-Year Return | 59.12% | 1.90% | Valencia Nutrition |
| Price-to-Sales Ratio (TTM) | 13.80 | 2.89 | Biocon |
| Enterprise Value | $892.32M | $610.01B | Biocon |
| EV/Revenue Ratio | 10.53 | 3.87 | Biocon |
| Gross Profit Margin (TTM) | -453.63% | 64.06% | Biocon |
| Revenue per Share (TTM) | $6 | $131 | Biocon |
| Earnings per Share (Diluted) | $0.76 | $3.19 | Biocon |
| Beta (Stock Volatility) | -0.11 | 0.23 | Valencia Nutrition |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Valencia Nutrition vs Biocon Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Valencia Nutrition | 3.39% | 4.99% | 17.44% | 45.65% | 43.67% | 43.67% |
| Biocon | -0.36% | -10.38% | -7.04% | 2.62% | -8.96% | -6.90% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Valencia Nutrition | 59.12% | 59.12% | 244.96% | 244.96% | 244.96% | 244.96% |
| Biocon | 1.90% | 10.35% | -13.10% | 338.90% | 501.00% | 841.46% |
Performance & Financial Health Analysis: Valencia Nutrition vs Biocon
| Metric | VALENCIA | BIOCON |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.17B | ₹456.09B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 15,600 | 4,512,546 |
| 90 Day Avg. Volume | 15,700 | 4,779,500 |
| Last Close | ₹71.15 | ₹342.10 |
| 52 Week Range | ₹35.80 - ₹72.00 | ₹291.00 - ₹406.00 |
| % from 52W High | -1.18% | -15.74% |
| All-Time High | ₹72.00 (Aug 11, 2025) | ₹487.75 (Dec 21, 2020) |
| % from All-Time High | -1.18% | -29.86% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 9.03% | 0.15% |
| Quarterly Earnings Growth | N/A | -0.95% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.02% |
| Operating Margin (TTM) | 0.34% | 0.07% |
| Return on Equity (TTM) | 0.06% | 0.04% |
| Debt to Equity (MRQ) | 4.06 | 66.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹26.32 | ₹180.66 |
| Cash per Share (MRQ) | ₹5.68 | ₹38.10 |
| Operating Cash Flow (TTM) | ₹-194,350,000 | ₹17.78B |
| Levered Free Cash Flow (TTM) | ₹-197,988,880 | ₹10.13B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.26% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Valencia Nutrition vs Biocon
| Metric | VALENCIA | BIOCON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 90.55 | 107.13 |
| Forward P/E | N/A | 34.45 |
| PEG Ratio | N/A | 34.45 |
| Price to Sales (TTM) | 13.80 | 2.89 |
| Price to Book (MRQ) | 2.61 | 1.89 |
| Market Capitalization | ||
| Market Capitalization | ₹1.17B | ₹456.09B |
| Enterprise Value | ₹892.32M | ₹610.01B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 10.53 | 3.87 |
| Enterprise to EBITDA | 62.94 | 18.91 |
| Risk & Other Metrics | ||
| Beta | -0.11 | 0.23 |
| Book Value per Share (MRQ) | ₹26.32 | ₹180.66 |
Financial Statements Comparison: Valencia Nutrition vs Biocon
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VALENCIA | BIOCON |
|---|---|---|
| Revenue/Sales | ₹1.29M | ₹39.10B |
| Cost of Goods Sold | ₹7.16M | ₹14.05B |
| Gross Profit | ₹-5.87M | ₹25.05B |
| Research & Development | N/A | ₹-346.00M |
| Operating Income (EBIT) | ₹-5.08M | ₹2.94B |
| EBITDA | ₹-4.87M | ₹8.29B |
| Pre-Tax Income | ₹-5.09M | ₹969.00M |
| Income Tax | ₹0 | ₹77.00M |
| Net Income (Profit) | ₹-5.09M | ₹892.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VALENCIA | BIOCON |
|---|---|---|
| Cash & Equivalents | ₹78.98M | ₹32.27B |
| Total Current Assets | ₹252.88M | ₹162.86B |
| Total Current Liabilities | ₹3.49M | ₹143.34B |
| Long-Term Debt | ₹14.87M | ₹129.45B |
| Total Shareholders Equity | ₹365.81M | ₹277.13B |
| Retained Earnings | N/A | ₹189.59B |
| Property, Plant & Equipment | ₹60.45M | ₹4.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VALENCIA | BIOCON |
|---|---|---|
| Operating Cash Flow | ₹-8.05M | N/A |
| Capital Expenditures | ₹-12.39M | N/A |
| Free Cash Flow | ₹-18.42M | N/A |
| Debt Repayment | ₹-516,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VALENCIA | BIOCON |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 15,600 | 4,512,546 |
| Average Daily Volume (90 Day) | 15,700 | 4,779,500 |
| Shares Outstanding | 16.98M | 1.20B |
| Float Shares | 3.65M | 523.49M |
| % Held by Insiders | 0.62% | 0.56% |
| % Held by Institutions | 0.00% | 0.23% |
Dividend Analysis & Yield Comparison: Valencia Nutrition vs Biocon
| Metric | VALENCIA | BIOCON |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.26% |
| 3-Year Avg Annual Dividend | N/A | ₹1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.36% |
| 3-Year Total Dividends | N/A | ₹4.00 |
| Ex-Dividend Date | N/A | Jul 04, 2025 |